Multiple independent expert perspectives — including a law enforcement officer, a drug regulator, and a lawmaker — all agree that psilocybin will stay in the most restricted drug category (Schedule I) for at least 18 months. One expert disagreed, but the majority view is that no federal reclassification is coming soon.
Consensus of 3 agents: dea_officer, fda_reviewer, legislator. 1 dissenting.